Parenteral Nutrition Market By Type of Nutrient (Carbohydrates, Lipid Emulsions, Amino Acids, Trace Elements, Vitamins & Minerals, Others), By Application (Gastrointestinal Disorders, Cancer Treatment, Post-Surgery Recovery, Chronic Diseases, Others), By Patient Type (Pediatric, Adult, Geriatric), By Distribution Channel (Hospitals, Home Care Settings, Specialty Clinics, Long-Term Care Facilities), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Parenteral Nutrition Market accounted for USD 7.76 Billion in 2024 and is expected to reach USD 16.0 Billion by 2035, growing at a CAGR of around 6.8% between 2025 and 2035. The parenteral nutrition market pertains to delivering nutrition by infusion to individuals who cannot take feed orally or enterally. This method is primarily used for patients with gastrointestinal diseases, cancer, undernutrition, or those who have undergone surgery.

Parenteral nutrition has often been defined as containing carbohydrates plus protein plus fat plus vitamins plus minerals. This publication establishes that the market has expanded as more people develop chronic illnesses, the population becomes older, and techniques in clinical nutrition improve. Parenteral nutrition can be delivered in hospitals, clinics specialized in nutritional support, and more and more in-home care settings. 

Report Scope:

Market Dynamics

Rising Malnutrition in Hospitalized Patients Fuels Demand for Parenteral Nutrition

One of the major growth factors of the parenteral nutrition market is the increasing incidence of malnutrition among hospital patients, which delays recovery and increasing the period of treatment. The primary causes of malnutrition generally include diseases, surgeries, and conditions such as cancer, gastrointestinal tract disorders, injuries, or trauma, which impair a patient's ability to receive nutrition either parenterally or enterally. As people live longer and diseases become more chronic, the global need for parenteral nutrition as nutritional support for critically ill individuals has risen.

The CDC reveals that in the USA at least one-third of the patients that are admitted to hospitals are malnourished or are at high risk of malnutrition. The demand for hybrid parenteral-enteral nutrition ingredients, essential for patients' prescriptions and their survival and recovery, has driven market growth.

Advancements in Clinical Nutrition Research Propel Patient-Specific Parenteral Solutions

Innovations in clinical nutrition research have become one of the main growth indicators for the parenteral nutrition market, with ongoing research increasing comprehension of individual nutritional requirements. In recent years there has been great emphasis placed on the ability to adjust the parenteral nutrition solutions according to the patient’s age, medical condition, and metabolism. These factors make the treatments both patient- and therapy-specific, thereby improving a patient’s prognosis, especially for those who are critically ill or possibly malnourished.

Specialized formulations for cancer patients, children, and patients with gastrointestinal disorders are wearing into the market, and this is working in favor of the market. There are constant innovations within the systems for nutrients, which are growing in the effectiveness and safety of IV and thus push the market forward. Increased understanding of the nutritive value and its influence on recovery and diseases translates to higher demand for tailor-made parenteral nutrition for patients and healthcare systems.

Insufficient Insurance Coverage Hampers Adoption of Parenteral Nutrition

The lack of adequate insurance is a major barrier that prevents the use of parenteral nutrition, particularly in areas with unclear or insufficient reimbursement policies. Parenteral nutrition enteral products, such as intravenous solutions and delivery systems, are very expensive, making it a financial strain to patients and healthcare providers whenever insurance coverage is inadequate. This places patients in a financially constrained situation, leading to delays in treatment or the exclusion of parenteral nutrition as an option for nursing critically ill and malnourished individuals.

In some countries, strict criteria for reimbursement or limited insurance coverage for home parenteral nutrition may deny access to this type of treatment, especially for home use. Thus, there is usually inadequate prescription of appropriate nutrients by many patients, thus reducing their recovery and general well-being. To address this barrier, healthcare systems and insurance companies should develop reimbursement models specifically for parenteral nutrition, recognizing it as a crucial component of outpatient care, especially as home care rapidly advances in the healthcare sector.

Rising Demand for Vegan Solutions Sparks Innovation in Plant-Based Lipid Emulsions

The growing consumer preference for vegan solutions presents a significant growth opportunity for the parenteral nutrition market, particularly in the development of plant-based lipid emulsions. Due to raised awareness of ‘green’ diets among consumers and preference for vegan and ethically sourced nutrients, solutions for parenteral nutrition without animal-based components are in high demand currently. This shift is currently applying pressure on companies to advance the processing of lipid emulsions derived from plant oils like soy and sunflower to meet the nutritional requirements of patients while at the same time observing the preferable vegan and vegetarian cultures.

Furthermore, the pharmacological consequences of plant-based lipid emulsions include the protection of the risks of allergic reactions and intolerance to animal-based fats. The increasing consumer preference for vegan solutions is a response to the increasing incidence of chronic diseases like cardiovascular disease and obesity, where plant-based solutions may be beneficial. This trend provides the pharmaceutical industry with a new opportunity to create innovative and sustainable patient-centric parenteral nutrition products that meet the diverse needs of a broader population, including individuals with specific nutritional requirements.

Strategic Collaborations with Biotechnology Firms Drive Innovation in Parenteral Nutrition

The parenteral nutrition market has a major opportunity in partnering with biotechnology firms, as the latter provide new nutrient formulation and delivery technologies. Such partnerships allow pharmaceutical companies to utilize the newest achievements of modern biotechnological progress in making the outcomes of parenteral nutrition therapies more efficient, safer, and individualized. Biotechnology companies possess special knowledge in the usage of genetic engineering, bioactive compounds, and innovative drug delivery techniques, which can be incorporated in parenteral nutrition products.

Altogether these can promote effective and efficient dietary therapies and interventions for subsets of clients like patients with rare diseases, critical illnesses, or metabolic disorders. Furthermore, biotechnology companies are more formally concentrating on developing the efficiency of nutrient procurement, and it provides eco-friendly solutions. Therefore, they not only promote the further development of solutions but expand the potential applications of parenteral nutrition.

Industry Experts Opinion

“After working on this research proposal for a long time, me and my research team are thrilled to be able to now conduct the study, and I am very thankful to the generous grant from Fresenius Kabi. I am very optimistic that this trial will have an impact on nutrition therapy in critical care.”

• Professor Stefan Schaller, M.D. of Charité – Universitätsmedizin Berlin, Germany

“We saw significant reductions in length of stay and days on parenteral nutrition, which directly translated to substantial cost savings for our NICU.”

• Dr. Rangasamy Ramanathan, professor of pediatrics division chief, division of neonatal medicine, Los Angeles General Medical Center and PIH Good Samaritan Hospital

Segment Analysis

Based on the type of nutrient, the parenteral nutrition market has been classified into Carbohydrates, Lipid Emulsions, Amino Acids, Trace Elements, Vitamins & Minerals, and Others. Based on the parenteral nutrition segments, amino acids take the majority share in the market because of their usefulness in restoring balanced and adequate nutrition in severely ill or malnourished patients. Because amino acids are ingredients in protein synthesis, repair of tissues, immune defense, and metabolic regulation, they are considered part of parenteral nutrition therapy. Thus, high demand results from their use in a wide range of diseases, including cancer, gastroenterological diseases, and in the postoperative period. Progress in modified amino acid products, including the development of products for patients with specific demands, has only enhanced concentration within the field.

Based on the application, the parenteral nutrition market has been classified into Gastrointestinal Disorders, Cancer Treatment, Post-Surgery Recovery, Chronic Diseases, and Others. Cancer treatment is the largest application segment of the parenteral nutrition market because patients suffering from cancer, especially those receiving chemotherapy, radiation therapy, or surgery, require high levels of nutritional intake due to illness and medical treatments.

Patients undergoing these treatments often develop severe malnutrition, necessitating parenteral nutrition to supply essential energy and improve their survival rates. Often cancer patients suffer such complications as mucositis, anorexia, or gastrointestinal mucositis that make oral or enteral feeding impossible. An increasing global cancer incidence and the development of adequate supportive care have escalated the prospect of using parenteral nutrition in oncology, thereby perpetuating the growth of this segment of the market.

Regional Analysis

North America has the largest parenteral nutrition market share due to advanced healthcare facilities, a high percentage of chronic disease patients, and an upswing in focused health consciousness amongst the consumer population. With an aging population, increasing incidences of cancer and gastrointestinal disorders have greatly increased the usage of parenteral nutrition therapies in the region. Since the products are specifically medical consumables or equipment, it is primarily aimed at the regional key players, including Baxter International Inc., Fresenius Kabi AG, and B. Braun Melsungen AG, who often engage in product launches and partnerships with healthcare organizations.

However, the growing demand for home healthcare services has expanded the market for parenteral nutrition applications beyond hospitals, allowing more patients to receive this treatment at home. Another factor that goes in the region’s favor is the favorable reimbursement policies and regulatory backup from bodies like the FDA. New changes like multiple chamber bags and lipid-based formulations targeting specific patient populations convey the increased focus of the region on the patient benefits.

The Asia-Pacific region is currently the fastest-growing parenteral nutrition market globally, driven by increased healthcare spending, a rising incidence of malnutrition, and the growing global burden of diseases such as cancer and diabetes. This growth is attributed to increased healthcare facilities and awareness about advanced nutrition therapies from Asian countries such as China, India, & Japan. There is a rapidly aging population, an increase in surgery, and hospitalization rates putting pressure on the demand for parenteral nutrition in this region.

Various players, domestic and global, are triggering a lot of interest in the market, especially seeing companies like Fresenius Kabi and Baxter International forming partnerships and production locations. There is a gradually increasing trend in the use of parenteral nutrition in-home care facilities, principally due to government policies that encourage better patient care. Each advanced nutrition therapy is becoming more affordable due to the implementation of cost-effective solutions and regulatory reforms, positively impacting market dynamics in the Asia-Pacific region compared to global competitors. 

Competitive Landscape

The competitive analysis of the market reveals that the parenteral nutrition market is a relatively consolidated market where key market players include Baxter International Inc., Fresenius Kabi AG, B. Braun Melsungen AG, Hospira, and Otsuka Pharmaceutical Co., Ltd. These firms have captured this market with their superior parenteral nutrition through IV nutrition solutions, amino acids, lipids, and vitamins.

Recent market activities include Baxter developing new parenteral nutrition solutions tailored for individual patient needs, while Fresenius Kabi is focused on expanding its product line with enhanced lipid emulsions and amino acid formulations. Some actors have paid attention to developing home care solutions, such as Otsuka and Nutricia, as the demand for at-home nutrition has increased. As consumers search for safer and more efficient ways to meet a range of therapeutic requirements, market competition is heightened by strategic partnerships between biotechnology firms and advancements in nutrient delivery mechanisms.

Parenteral Nutrition Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In September 2021, Fresenius Kabi proudly announced the winner of its JUMPstart education program and research grant. This innovative initiative supports advancements in parenteral nutrition by fostering research through mentoring, education, and networking opportunities for clinicians and researchers. The grant is designed to promote community-driven research in parenteral nutrition, aiming to improve outcomes for critically ill patients.
• In July 2020, Baxter International, a leading player in clinical nutrition, including parenteral nutrition solutions, formed a joint venture with VIPUN Medical, a pioneer in technology development. This partnership aims to enhance the medical nutrition segment. The agreement focused on commercializing the VIPUN gastric monitoring system, designed for patients who are intolerant to enteral nutrition. Baxter's parenteral nutrition products complement this system, ensuring patients receive their necessary nutritional support.

Report Coverage:

By Type of Nutrient

• Carbohydrates
• Lipid Emulsions
• Amino Acids
• Trace Elements
• Vitamins & Minerals
• Others

By Application

• Gastrointestinal Disorders
• Cancer Treatment
• Post-Surgery Recovery
• Chronic Diseases
• Others  

By Patient Type

• Pediatric
• Adult
• Geriatric

By Distribution Channel

• Hospitals
• Home Care Settings
• Specialty Clinics
• Long-Term Care Facilities

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Baxter International Inc.
• B. Braun Melsungen AG
• Hospira
• Fresenius Kabi AG
• Vifor Pharma
• Otsuka Pharmaceutical Co., Ltd.
• Terumo Corporation
• McGaw, Inc.
• Nutricia
• Amgen Inc.
• Medi-Flex
• Marathon Pharmaceuticals
• Calea Ltd.
• Grifols S.A.
• Sandoz

Frequently Asked Questions (FAQs)